Ipsen (OTCMKTS:IPSEY) Share Price Crosses Above 200 Day Moving Average of $26.27

Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $26.27 and traded as high as $27.47. Ipsen shares last traded at $27.45, with a volume of 1,059 shares trading hands.

Wall Street Analyst Weigh In

IPSEY has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Ipsen from C$91.00 to C$115.00 in a research report on Monday, November 21st. Jefferies Financial Group started coverage on shares of Ipsen in a report on Friday, December 2nd. They set a “buy” rating for the company. Morgan Stanley raised shares of Ipsen from an “underweight” rating to an “equal weight” rating in a research note on Thursday, February 16th. Oddo Bhf cut shares of Ipsen from an “outperform” rating to a “neutral” rating in a research note on Friday, December 9th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Ipsen from €90.00 ($96.77) to €95.00 ($102.15) and gave the stock a “hold” rating in a research note on Thursday, January 12th. Nine equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $106.00.

Ipsen Price Performance

The stock’s fifty day moving average is $27.76 and its two-hundred day moving average is $26.27.

About Ipsen

(Get Rating)

Ipsen SA engages in the manufacture of pharmaceutical products for oncology, neuroscience and rare diseases. It focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.